A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 18 Jul 2019 Planned End Date changed from 14 Jan 2022 to 11 Dec 2021.
- 18 Jul 2019 Status changed from not yet recruiting to recruiting.
- 28 May 2019 Planned End Date changed from 13 Dec 2021 to 14 Jan 2022.